BCM
PRLD icon

Boxer Capital Management’s Prelude Therapeutics PRLD Stock Holding History

Boxer Capital Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,108,014
Closed -$1.62M – 29
2025
Q1 		$1.62M Buy
2,108,014
+399,827
+23% +$373K 0.49% 23
2024
Q4 		$2.18M Buy
+1,708,187
New +$2.27M 0.19% 50

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Boxer Capital Management's PRLD Position: Q2 2025 in Review

Boxer Capital Management sold out of Prelude Therapeutics (PRLD) in Q2 2025, closing a stake of 2,108,014 shares — an estimated $1.62M sold.

Boxer Capital Management first reported a position in PRLD in Q4 2024 and held it in 2 quarters. The position peaked at $2.18M in Q4 2024. 50 funds tracked by Wall St. Rank hold PRLD as of Q2 2025.

  • Boxer Capital Management reported no remaining Prelude Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Boxer Capital Management sold 2,108,014 Prelude Therapeutics shares in Q2 2025, an estimated $1.62M.
  • Boxer Capital Management first reported a position in Prelude Therapeutics in Q4 2024 and held it in 2 quarters.
  • Boxer Capital Management's Prelude Therapeutics position peaked at $2.18M in Q4 2024.
  • 50 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2025.

Based on Boxer Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.